Orphan designation for Novartis’ branaplam in Huntington’s disease

Novartis’ branaplam (LMI070) has gained Orphan Drug Designation in the US in Huntington’s disease (HD).

In preclinical models, branaplam has been shown to reduce levels of mutant huntingtin protein. In addition, during the investigation of branaplam in spinal muscular atrophy (SMA), it was also observed to reduce huntingtin messenger RNA (mRNA) in SMA patients.

A decrease of huntingtin mRNA is expected to result in reduction of huntingtin protein levels, the underlying cause of HD.

Based on these findings, Novartis intends to start a development program for branaplam to determine if it has the potential to be a transformative treatment for people living with this devastating condition.

Branaplam is currently under investigation for the treatment SMA.  It is dosed once weekly for the treatment of SMA, and the same dosing regimen may also be a possibility for HD.

Novartis plans to start the Phase IIb trial for branaplam in HD patients in 2021.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news